Browsing by Author "Ibrahim, I.A."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Article
    Citation - Scopus: 0
    Plasma-Exchange Therapy in Acute Immune-Mediated Neuropathy: Effects on Muscle Strength and Functional Outcomes
    (Amaltea Medical Publishing House, 2024) Khosa, N.A.; Essa, S.M.; Zarak, M.S.; Zarkoon, A.U.H.; Ibrahim, I.A.; Mumtaz, T.
    Background and objectives. This study explores the impact of plasma exchange therapy (TPE) on muscle strength and functional outcomes in patients with acute immune-mediated neuropathy. Materials and methods. We retrospectively analyzed clinical data from patients diagnosed with acute immune-mediated neuropathy at the Department of Neurology, Bolan University of Medical Sciences, Baluchistan, from January 2016 to December 2021. Results. The study, comprising 141 patients with various neurological disorders, underscores the efficacy of plasma exchange therapy in improving muscle strength and functional outcomes, particularly in Guillain-Barré Syndrome (GBS). Notably, after four weeks of treatment, a significant proportion of patients demonstrated improved mobility, with 51.8% able to walk without assistance. However, despite the positive response to therapy, a small percentage (2.8%) experienced unfavorable outcomes marked by expiration. Additionally, the study identifies significant associations between treatment outcomes and patient characteristics, such as the number of plasma exchange cycles and diagnosis (p <0.05), emphasizing the importance of personalized treatment approaches in managing neurological disorders. Conclusions. Our findings underscore the effectiveness of plasma exchange in enhancing muscle strength and functional outcomes in acute immune-mediated neuropathy, particularly GBS. © 2024, Amaltea Medical Publishing House. All rights reserved.
  • Thumbnail Image
    Review
    Citation - Scopus: 0
    Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 1 and Type 2 Diabetes Mellitus: a Systematic Review and Meta-Analysis
    (Taylor and Francis Ltd., 2025) Nada, A.H.; Ibrahim, I.A.; Oteri, V.; Shalabi, L.; Asar, N.K.; Aqeilan, S.R.; Hafez, W.
    Introduction: Many patients struggle to control glucose without side effects. Due to their immunomodulatory and regenerative properties, mesenchymal stem cells (MSCs) might treat Diabetes Mellitus (DM). The authors employed this meta-analysis to evaluate the efficacy and safety of umbilical cord MSCs (UCMSCs) for DM management. Methods: The PubMed, Cochrane, WOS, Embase, and Scopus databases were searched for randomized controlled trials (RCTs) investigating the effects of UCMSCs on DM (Types 1, 2) till January 2024. Patient demographics, interventions, and outcomes, including glycated hemoglobin (HbA1c%), C-peptide levels, and insulin requirements, were extracted. A comprehensive meta-analysis software was used. Results: Eight CTs of 334 patients (172 experimental and 162 controls) were included. UMSCs treatment substantially lowered HbA1c levels (MD = -1.06, 95% CI [−1.27, −0.85], p < 0.00001) with consistent outcomes (i2 = 0%, p = 0.43). Fasting C-peptide levels were heterogeneous but favored placebo (MD = 0.35, 95% CI [0.15, 0.56], p = 0.0007). In T1D patients, daily insulin requirements decreased considerably (MD = -0.24, 95% CI [−0.29, −0.18], p < 0.00001), with heterogeneity addressed by sensitivity analysis. Conclusion: UMSCs therapy reduced HbA1c and insulin requirements, and increased C-peptide levels. Multicenter clinical trials are required to confirm the long-term efficacy and safety of UMSC therapy. © 2025 Informa UK Limited, trading as Taylor & Francis Group.